Search results
Results From The WOW.Com Content Network
Despite operating for nearly two decades without profit, 23andMe went public in 2021 and reached a $6 billion valuation. The company's stocks were priced at $11.13 a share, but they've fallen ...
The Food and Drug Administration decided that 23andMe’s test and health reports about a person’s predisposition to various diseases circumvented the regulator.
Anne Wojcicki, CEO of 23andMe, the struggling DNA testing company, doesn’t think this is the right time to examine her leadership style.“What will be most interesting is writing the story in ...
Three-quarters of Lemonaid's $400 million acquisition was paid as shares of 23andMe stock. 23andMe was valued at $3.5 billion when it went public in 2021. On Friday it was valued at about $91 million.
23andMe continued to evolve its services, and in 2015, the FDA granted authorization to market its screening for Bloom syndrome, a rare genetic disorder, the company said at the time.
Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring ...
Millions of people use genetic testing companies like 23andMe to learn more about their ancestry and health. But a new data breach is highlighting the risks of having your ancestry information ...
Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety.